Display options
Cite
Menis J, Reck M. Checkpoint Inhibitors in SCLC: How Much Can We Trust in Randomized Cohorts of Phase I/II Trials?. J Thorac Oncol. 2020;15(3):308-310doi: 10.1016/j.jtho.2019.11.031.
Menis, J., & Reck, M. (2020). Checkpoint Inhibitors in SCLC: How Much Can We Trust in Randomized Cohorts of Phase I/II Trials?. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 15(3), 308-310. https://doi.org/10.1016/j.jtho.2019.11.031
Menis, Jessica, and Reck, Martin. "Checkpoint Inhibitors in SCLC: How Much Can We Trust in Randomized Cohorts of Phase I/II Trials?." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer vol. 15,3 (2020): 308-310. doi: https://doi.org/10.1016/j.jtho.2019.11.031
Menis J, Reck M. Checkpoint Inhibitors in SCLC: How Much Can We Trust in Randomized Cohorts of Phase I/II Trials?. J Thorac Oncol. 2020 Mar;15(3):308-310. doi: 10.1016/j.jtho.2019.11.031. PMID: 32093850.
Copy Download .nbib Format: NLM
Share it on

J Thorac Oncol. 2020 Mar;15(3):308-310. doi: 10.1016/j.jtho.2019.11.031.

Checkpoint Inhibitors in SCLC: How Much Can We Trust in Randomized Cohorts of Phase I/II Trials?.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Jessica Menis, Martin Reck

Affiliations

  1. Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Medical Oncology Department, Istituto Oncologico Veneto IRCCS, Padova, Italy. Electronic address: [email protected].
  2. LungenClinic, Airway Research Center North (ARCN), German Center for Lung Research, Grosshansdorf, Germany.

PMID: 32093850 DOI: 10.1016/j.jtho.2019.11.031

[No abstract available.]

Substances

MeSH terms

Publication Types